<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333174</url>
  </required_header>
  <id_info>
    <org_study_id>UAB Neo 020</org_study_id>
    <nct_id>NCT03333174</nct_id>
  </id_info>
  <brief_title>Prematurity Related Ventilatory Control (PRE-VENT) - Specific Aim 3</brief_title>
  <official_title>Prematurity-Related Ventilatory Control (PRE-VENT): Role in Respiratory Outcomes Clinical Research Centers (CRC) - Specific Aim 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if servo-controlled oxygen environment is associated with reduction in (a)&#xD;
      bradycardia events, (b) hypoxemic time, (c) bradycardia time, (d) apneic episodes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll the subset of infants enrolled in the main study (PreVENT Aim 1;&#xD;
      401-1000g at birth and/or 22w 0d-28w 6d; enrolled at &lt;1 week postnatal age; eligible for full&#xD;
      care and surviving beyond 24 hours, with informed consent; and with no major malformations)&#xD;
      who are receiving oxygen supplementation at 32w and 36w postmenstrual age (PMA), and are not&#xD;
      judged too unstable by the Attending neonatologist.&#xD;
&#xD;
      For infants on oxygen supplementation at 32w PMA, the investigators will use data from the 96&#xD;
      hours of intensive multiparametric physiologic monitoring at 32w PMA. For infants on oxygen&#xD;
      supplementation at 36w PMA, we will use the 96 hours of intensive multiparametric physiologic&#xD;
      monitoring at 36w PMA as well as data from the sleep study.&#xD;
&#xD;
      The first 24 hours of data collection will be the baseline data. Over the next 72 hours, the&#xD;
      investigators will evaluate 3 interventions in a cross-over manner with the initial&#xD;
      intervention (cannula or oxygen environment) randomly assigned: Intervention 1 (24-48h of&#xD;
      data), Intervention 2 (48-72h of data) and Intervention 3 (72-96h of data).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2018</start_date>
  <completion_date type="Actual">July 1, 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>(b) The first 24h of the data collection will be the baseline data. Over the next 72h, we will evaluate 3 interventions in a cross-over manner: Intervention 1 (24-48h of data), Intervention 2 (48-72h), and Intervention 3 (72-96h; same as intervention 1). Initial intervention will be by random assignment (computer-generated). The intervention will be to provide oxygen either by nasal cannula or by servo-controlled oxygen environment, followed by cross-over to other intervention for 24h, and then back to original intervention.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hypoxemic episode</measure>
    <time_frame>During 24 hour time periods with either intervention (nasal cannula vs. oxygen environment)</time_frame>
    <description>Hypoxemic episode defined as as oxygen saturation by pulse oximetry (SpO2) &lt;85% for &gt;10 seconds</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bradycardic episode</measure>
    <time_frame>During 24 hour time periods with either intervention (nasal cannula vs. oxygen environment)</time_frame>
    <description>Bradycardic episode defined as heart rate (HR) &lt;100/min for &gt;10 seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apnea episodes</measure>
    <time_frame>During 24 hour time periods with either intervention (nasal cannula vs. oxygen environment)</time_frame>
    <description>Apnea defined as Respiratory Rate (RR)=0 for &gt;20 seconds, or RR=0 for &gt;10 seconds + oxygen saturation by pulse oximetry (SpO2) &lt;85% or heart rate (HR) &lt;100/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoxemic time defined as duration of time with SpO2 &lt;85%</measure>
    <time_frame>During 24 hour time periods with either intervention (nasal cannula vs. oxygen environment)</time_frame>
    <description>Hypoxemic time defined as duration of time with SpO2 &lt;85%</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Infant,Premature</condition>
  <arm_group>
    <arm_group_label>Servo-controlled Oxygen Environment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxygen will be provided by servo-controlled oxygen environment with adjustment of oxygen concentration (FiO2) to keep infant's oxygen saturation target range at 91-95% in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal Cannula Oxygen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxygen will be provided by nasal cannula with adjustment of flow rate and FiO2 to keep infant's oxygen saturation target range at 91-95% in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiorespiratory monitoring</intervention_name>
    <description>The investigators will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations)</description>
    <arm_group_label>Nasal Cannula Oxygen</arm_group_label>
    <arm_group_label>Servo-controlled Oxygen Environment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Inborn infants weighing 401-1,000 grams on admission and/or 22w 0/7d to 28w 6/7d (&lt;29&#xD;
        weeks) inclusive completed weeks of gestation&#xD;
&#xD;
        Infants eligible for full care and resuscitation as necessary, and surviving beyond 24 h of&#xD;
        age&#xD;
&#xD;
        Enrollment in main study protocol (Aim 1 of PreVENT Apnea) at &lt;1 week post-natal age&#xD;
&#xD;
        This study will enroll the subset of infants from Aim 1 who are receiving oxygen&#xD;
        supplementation at 32w and 36w PMA, and are not judged too unstable by the Attending&#xD;
        neonatologist&#xD;
&#xD;
        Informed consent from parent/guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Refusal or withdrawal of consent Major congenital malformations (e.g., not including&#xD;
        patent ductus arteriosus, small hernia)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>98 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Namasivayam Ambalavanan</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regional Neonatal ICU and CCN, University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 2, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Namasivayam Ambalavanan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>apnea of prematurity</keyword>
  <keyword>bradycardia</keyword>
  <keyword>hypoxemic episode</keyword>
  <keyword>oxygen delivery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT03333174/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

